A citation-based method for searching scientific literature

Yi-Long Wu, James Chih-Hsin Yang, Dong-Wan Kim, Shun Lu, Jianying Zhou, Takashi Seto, Jin-Ji Yang, Noboru Yamamoto, Myung-Ju Ahn, Toshiaki Takahashi, Takeharu Yamanaka, Allison Kemner, Debasish Roychowdhury, Jolanda Paolini, Tiziana Usari, Keith D Wilner, Koichi Goto. J Clin Oncol 2018
Times Cited: 129



Justin F Gainor, Diane Tseng, Satoshi Yoda, Ibiayi Dagogo-Jack, Luc Friboulet, Jessica J Lin, Harper G Hubbeling, Leila Dardaei, Anna F Farago, Katherine R Schultz, Lorin A Ferris, Zofia Piotrowska, James Hardwick, Donghui Huang, Mari Mino-Kenudson, A John Iafrate, Aaron N Hata, Beow Y Yeap, Alice T Shaw. JCO Precis Oncol 2017
Times Cited: 120




List of shared articles



Times cited

ROS1-dependent cancers - biology, diagnostics and therapeutics.
Alexander Drilon, Chelsea Jenkins, Sudarshan Iyer, Adam Schoenfeld, Clare Keddy, Monika A Davare. Nat Rev Clin Oncol 2021
22

Acquired MET D1228N Mutations Mediate Crizotinib Resistance in Lung Adenocarcinoma with ROS1 Fusion: A Case Report.
Yu Wang, Zheng Chen, Xiao Han, Jiamei Li, Honglin Guo, Junping Shi. Oncologist 2021
4

Targeting Infrequent Driver Alterations in Non-Small Cell Lung Cancer.
Marie-Julie Nokin, Chiara Ambrogio, Ernest Nadal, David Santamaria. Trends Cancer 2021
3

Different clinical features between patients with ROS1-positive and ALK-positive advanced non-small cell lung cancer.
Xianxiu Ji, Huikang Xie, Ren Zhu, Bin Chen, Sen Jiang, Jie Luo. J Int Med Res 2021
0

Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Locally Advanced or Metastatic ROS1 Fusion-Positive Non-Small-Cell Lung Cancer.
Rafal Dziadziuszko, Matthew G Krebs, Filippo De Braud, Salvatore Siena, Alexander Drilon, Robert C Doebele, Manish R Patel, Byoung Chul Cho, Stephen V Liu, Myung-Ju Ahn,[...]. J Clin Oncol 2021
5

Spectrum of Mechanisms of Resistance to Crizotinib and Lorlatinib in ROS1 Fusion-Positive Lung Cancer.
Jessica J Lin, Noura J Choudhury, Satoshi Yoda, Viola W Zhu, Ted W Johnson, Ramin Sakhtemani, Ibiayi Dagogo-Jack, Subba R Digumarthy, Charlotte Lee, Andrew Do,[...]. Clin Cancer Res 2021
2

Uncommon targets in non-small cell lung cancer: Everyone wants a slice of cake.
Alessandro De Toma, Giuseppe Lo Russo, Diego Signorelli, Filippo Pagani, Giovanni Randon, Giulia Galli, Arsela Prelaj, Roberto Ferrara, Claudia Proto, Monica Ganzinelli,[...]. Crit Rev Oncol Hematol 2021
2

Meningeal "Lazarus Response" to Lorlatinib in a ROS1-Positive NSCLC Patient Progressing to Entrectinib.
Francesco Facchinetti, Antonin Levy, Samy Ammari, Charles Naltet, Pernelle Lavaud, Mihaela Aldea, Damien Vasseur, David Planchard, Benjamin Besse. Cancer Manag Res 2021
0

Treatment of Rare Mutations in Patients with Lung Cancer.
Tarek Taha, Rasha Khoury, Ronen Brenner, Haitam Nasrallah, Irena Shofaniyeh, Samih Yousef, Abed Agbarya. Biomedicines 2021
0

ROS1 Targeted Therapies: Current Status.
Christine M Azelby, Mandy R Sakamoto, Daniel W Bowles. Curr Oncol Rep 2021
2

Lung cancer.
Alesha A Thai, Benjamin J Solomon, Lecia V Sequist, Justin F Gainor, Rebecca S Heist. Lancet 2021
8

Entrectinib for ROS1-rearranged non-small cell lung cancer after crizotinib-induced interstitial lung disease: A case report.
Mai Tanimura, Nobutaka Kataoka, Yusuke Kunimatsu, Rei Tsutsumi, Izumi Sato, Takayuki Nakano, Keiko Tanimura, Takayuki Takeda. Respirol Case Rep 2021
0

Recent advances in lung cancer genomics: Application in targeted therapy.
Neha Pathak, Sindhura Chitikela, Prabhat Singh Malik. Adv Genet 2021
1

Deepening the Knowledge of ROS1 Rearrangements in Non-Small Cell Lung Cancer: Diagnosis, Treatment, Resistance and Concomitant Alterations.
Giorgia Guaitoli, Federica Bertolini, Stefania Bettelli, Samantha Manfredini, Michela Maur, Lucia Trudu, Beatrice Aramini, Valentina Masciale, Giulia Grisendi, Massimo Dominici,[...]. Int J Mol Sci 2021
0

Computed Tomography Imaging Features and Distribution of Metastases in ROS1-rearranged Non-Small-cell Lung Cancer.
Subba R Digumarthy, Dexter P Mendoza, Jessica J Lin, Tianqi Chen, Marguerite M Rooney, Emily Chin, Lecia V Sequist, Jochen K Lennerz, Justin F Gainor, Alice T Shaw. Clin Lung Cancer 2020
12

Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials.
Alexander Drilon, Salvatore Siena, Rafal Dziadziuszko, Fabrice Barlesi, Matthew G Krebs, Alice T Shaw, Filippo de Braud, Christian Rolfo, Myung-Ju Ahn, Jürgen Wolf,[...]. Lancet Oncol 2020
112

Crizotinib vs platinum-based chemotherapy as first-line treatment for advanced non-small cell lung cancer with different ROS1 fusion variants.
Haiyan Xu, Quan Zhang, Li Liang, Junling Li, Zhefeng Liu, Weihua Li, Lu Yang, Guangjian Yang, Fei Xu, Jianming Ying,[...]. Cancer Med 2020
6

Entrectinib for the treatment of metastatic NSCLC: safety and efficacy.
Andrea Sartore-Bianchi, Elio Gregory Pizzutilo, Giovanna Marrapese, Federica Tosi, Giulio Cerea, Salvatore Siena. Expert Rev Anticancer Ther 2020
9

ROS1-rearranged Non-small Cell Lung Cancer.
Nicholas P Giustini, Lyudmila Bazhenova. Thorac Surg Clin 2020
2

Clinical activity of brigatinib in ROS1-rearranged non-small cell lung cancer.
E Dudnik, A Agbarya, R Grinberg, A Cyjon, J Bar, M Moskovitz, N Peled. Clin Transl Oncol 2020
1

Cases of ROS1-rearranged lung cancer: when to use crizotinib, entrectinib, lorlatinib, and beyond?
Kartik Sehgal, Andrew J Piper-Vallillo, Hollis Viray, Adeel M Khan, Deepa Rangachari, Daniel B Costa. Precis Cancer Med 2020
8


Focus on ROS1-Positive Non-Small Cell Lung Cancer (NSCLC): Crizotinib, Resistance Mechanisms and the Newer Generation of Targeted Therapies.
Alberto D'Angelo, Navid Sobhani, Robert Chapman, Stefan Bagby, Carlotta Bortoletti, Mirko Traversini, Katia Ferrari, Luca Voltolini, Jacob Darlow, Giandomenico Roviello. Cancers (Basel) 2020
10


Overcoming TKI resistance in fusion-driven NSCLC: new generation inhibitors and rationale for combination strategies.
Alessandro Russo, Andrés F Cardona, Christian Caglevic, Paolo Manca, Alejandro Ruiz-Patiño, Oscar Arrieta, Christian Rolfo. Transl Lung Cancer Res 2020
3

How selecting best upfront therapy for metastatic disease?-Focus on ROS1-rearranged disease.
Lorenza Landi, Federico Cappuzzo. Transl Lung Cancer Res 2020
0



Safety and Efficacy of Crizotinib in Patients With Advanced or Metastatic ROS1-Rearranged Lung Cancer (EUCROSS): A European Phase II Clinical Trial.
Sebastian Michels, Bartomeu Massutí, Hans-Ulrich Schildhaus, Jeremy Franklin, Martin Sebastian, Enriqueta Felip, Christian Grohé, Delvys Rodriguez-Abreu, Diana S Y Abdulla, Helge Bischoff,[...]. J Thorac Oncol 2019
34

Advanced-Stage Non-Small Cell Lung Cancer: Advances in Thoracic Oncology 2018.
Jordi Remon, Myung-Ju Ahn, Nicolas Girard, Melissa Johnson, Dong-Wan Kim, Gilberto Lopes, Rathi N Pillai, Benjamin Solomon, Guillermo Villacampa, Qing Zhou. J Thorac Oncol 2019
41